Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill

Hims & Hers Health, Inc. (NYSE:HIMS) today announced that a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and delivery methods. This expansion makes Hims & Hers the largest global consumer health platform for affordable access to approved medications.

 

Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill.

Based on an independent provider's clinical decision, eligible Hims & Hers customers can now access Novo Nordisk treatments that can help them lose up to 20% of their body weight.2 Medication options include Wegovy® (semaglutide) 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg injection and 1.5 mg, 4 mg, 9 mg, and 25 mg pills, with Wegovy® (semaglutide) 7.2 mg injection coming soon. Ozempic® (semaglutide) 0.25 mg, 0.5 mg, 1 mg, and 2 mg injection pens, which are approved as treatments for Type 2 diabetes, will also be available for eligible patients based on individual clinical judgment. Ozempic is not FDA-approved for weight loss. Prices start as low as $149 a month.3